secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K/A
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001437749-25-014334
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton withdraws SEC waiver request for Increlex financials; expects filing in Q3 2025
--------------------------------------------------------------------------------

- Company had requested a waiver from filing historical audited financials and pro forma statements for Increlex.
- After discussions with SEC on unique accounting treatment, waiver request was withdrawn.
- Eton now expects to prepare and file the required financial statements in Q3 2025.
- Several factors could still delay the filing beyond Q3 2025.
- Acquisition of Increlex from Ipsen closed on December 19, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925014334/0001437749-25-014334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925014334/eton20250426_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer